<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40970105</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2398-8835</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Health science reports</Title><ISOAbbreviation>Health Sci Rep</ISOAbbreviation></Journal><ArticleTitle>The Prevalence of Cardiovascular Disease Risk Factors on Diabetic Human Immunodeficiency Virus-Infected Individuals on Antiretroviral Treatment: A Systematic Review and Meta-Analysis Protocol.</ArticleTitle><Pagination><StartPage>e71274</StartPage><MedlinePgn>e71274</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e71274</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/hsr2.71274</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="UNASSIGNED">People with human immunodeficiency virus (PLWHIV) have a higher prevalence of non-communicable diseases (NCDs) such as obesity, diabetes mellitus and cardiovascular diseases (CVDs). Previous studies have depicted that PLWHIV have these NCDs due to the predisposing risk factors of CVDs including dyslipidaemia, impaired fasting glucose, hypertension, obesity, and elevated glycated hemoglobin. Understanding the cumulative consequences of these disorders is critical in this population. Hence, the aim of this protocol is to narrate the methods and techniques that will be used to perform a systematic review and meta-analysis of the prevalence of various CVD risk factors among diabetic individuals receiving antiretroviral therapy. Furthermore, this review will explore the extent to which traditional and HIV-specific risk factors contribute to the beginning and progression of CVD in the HIV-positive population by merging available data.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Literature search will be conducted using selected keywords on databases such as PubMed, Google Scholar, Scopus, and Web of science to identify eligible publications according to the eligibility criteria. Preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines will be used for reporting and risk of bias will be assessed using the Cochrane Risk of Bias In Non-randomized Studies of Interventions (ROBINS-I tool). Data synthesis and sensitivity analysis will be performed using RevMan software and strength of evidence will be assessed using the grading of recommendations assessment, development, and evaluation approach (GRADE) pro tool.</AbstractText><AbstractText Label="ETHICAL CONSIDERATIONS AND REGISTRATION" NlmCategory="UNASSIGNED">This systematic review protocol is registered with PROSPERO (CRD42024524396) and it doesn't require any ethical clearance as it will use data from published reports.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Health Science Reports published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maswanganyi</LastName><ForeName>Khanyisa</ForeName><Initials>K</Initials><Identifier Source="ORCID">0009-0009-3714-5338</Identifier><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Health Sciences University of Pretoria Gauteng South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedibe</LastName><ForeName>Amogelang</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Health Sciences University of Pretoria Gauteng South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mzimela</LastName><ForeName>Nomusa Christina</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>School of Laboratory Medicine and Medical Science, College of Health Sciences University of Kwa-Zulu Natal Durban South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamede</LastName><ForeName>Mlindeli</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Health Sciences University of Pretoria Gauteng South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Health Sci Rep</MedlineTA><NlmUniqueID>101728855</NlmUniqueID><ISSNLinking>2398-8835</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">T2DM and ART</Keyword><Keyword MajorTopicYN="N">cardiovascular disease and ART</Keyword><Keyword MajorTopicYN="N">dyslipidaemia and HIV/ARVs</Keyword><Keyword MajorTopicYN="N">glycated hemoglobin and ART</Keyword><Keyword MajorTopicYN="N">hypercholesterolemia and HIV/ARVs</Keyword><Keyword MajorTopicYN="N">hypertension and ART</Keyword><Keyword MajorTopicYN="N">hypertriglyceridemia and ART</Keyword><Keyword MajorTopicYN="N">impaired fasting glucose and ART</Keyword><Keyword MajorTopicYN="N">obesity and ART</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>19</Day><Hour>5</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40970105</ArticleId><ArticleId IdType="pmc">PMC12440799</ArticleId><ArticleId IdType="doi">10.1002/hsr2.71274</ArticleId><ArticleId IdType="pii">HSR271274</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Balakumar P., Maung&#x2010;U K., and Jagadeesh G., &#x201c;Prevalence and Prevention of Cardiovascular Disease and Diabetes Mellitus,&#x201d; Pharmacological Research 113 (2016): 600&#x2013;609, 10.1016/j.phrs.2016.09.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2016.09.040</ArticleId><ArticleId IdType="pubmed">27697647</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumare J., Dakum P., Sam&#x2010;Agudu N., et al., &#x201c;Prevalence and Characteristics of Metabolic Syndrome and Its Components Among Adults Living With and Without HIV in Nigeria: A Single&#x2010;Center Study,&#x201d; BMC Endocrine Disorders 23, no. 1 (2023): 160, 10.1186/s12902-023-01419-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12902-023-01419-x</ArticleId><ArticleId IdType="pmc">PMC10375691</ArticleId><ArticleId IdType="pubmed">37507703</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyo&#x2010;Chilufya M., Maluleke K., Kgarosi K., Muyoyeta M., Hongoro C., and Musekiwa A., &#x201c;The Burden of Non&#x2010;Communicable Diseases Among People Living With HIV in Sub&#x2010;Saharan Africa: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Eclinicalmedicine 65 (2023): 102255, 10.1016/j.eclinm.2023.102255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102255</ArticleId><ArticleId IdType="pmc">PMC10570719</ArticleId><ArticleId IdType="pubmed">37842552</ArticleId></ArticleIdList></Reference><Reference><Citation>
Organisation WH [Internet]
, Global HIV/AIDS statistics (2021), https://www.who.int/hiv/data/global_hiv_epidemic_response/en/.</Citation></Reference><Reference><Citation>Hernandez&#x2010;Romieu A. C., Garg S., Rosenberg E. S., Thompson&#x2010;Paul A. M., and Skarbinski J., &#x201c;Is Diabetes Prevalence Higher Among HIV&#x2010;Infected Individuals Compared With the General Population? Evidence From Mmp and NHANES 2009&#x2013;2010,&#x201d; BMJ Open Diabetes Research &amp; Care 5, no. 1 (2017): e000304, 10.1136/bmjdrc-2016-000304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2016-000304</ArticleId><ArticleId IdType="pmc">PMC5293823</ArticleId><ArticleId IdType="pubmed">28191320</ArticleId></ArticleIdList></Reference><Reference><Citation>Einarson T. R., Acs A., Ludwig C., and Panton U. H., &#x201c;Prevalence of Cardiovascular Disease in Type 2 Diabetes: A Systematic Literature Review of Scientific Evidence From Across the World in 2007&#x2013;2017,&#x201d; Cardiovascular Diabetology 17, no. 1 (2018): 83, 10.1186/s12933-018-0728-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-018-0728-6</ArticleId><ArticleId IdType="pmc">PMC5994068</ArticleId><ArticleId IdType="pubmed">29884191</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheus A. S. M., Tannus L. R. M., Cobas R. A., Palma C. C. S., Negrato C. A., and Gomes M. B., &#x201c;Impact of Diabetes on Cardiovascular Disease: An Update,&#x201d; International Journal of Hypertension 2013 (2013): 1&#x2013;15, 10.1155/2013/653789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/653789</ArticleId><ArticleId IdType="pmc">PMC3603160</ArticleId><ArticleId IdType="pubmed">23533715</ArticleId></ArticleIdList></Reference><Reference><Citation>Leon B. M., &#x201c;Diabetes and Cardiovascular Disease: Epidemiology, Biological Mechanisms, Treatment Recommendations and Future Research,&#x201d; World Journal of Diabetes 6, no. 13 (2015): 1246&#x2013;1258, 10.4239/wjd.v6.i13.1246.</Citation><ArticleIdList><ArticleId IdType="doi">10.4239/wjd.v6.i13.1246</ArticleId><ArticleId IdType="pmc">PMC4600176</ArticleId><ArticleId IdType="pubmed">26468341</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph J. J., Deedwania P., Acharya T., et al., &#x201c;Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association,&#x201d; Circulation 145, no. 9 (2022): e722&#x2013;e759, 10.1161/CIR.0000000000001040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001040</ArticleId><ArticleId IdType="pubmed">35000404</ArticleId></ArticleIdList></Reference><Reference><Citation>
Verhaegen A. A. and Van Gaal L. F., &#x201c;Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism,&#x201d; Endotext [Internet] (2019), https://www.ncbi.nlm.nih.gov/books/NBK537590/.</Citation></Reference><Reference><Citation>Thet D. and Siritientong T., &#x201c;Antiretroviral Therapy&#x2010;Associated Metabolic Complications: Review of the Recent Studies,&#x201d; HIV/AIDS&#x2010;Research and Palliative Care 12 (2020): 507&#x2013;524, 10.2147/HIV.S275314.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/HIV.S275314</ArticleId><ArticleId IdType="pmc">PMC7537841</ArticleId><ArticleId IdType="pubmed">33061662</ArticleId></ArticleIdList></Reference><Reference><Citation>Honnapurmath V. and Patil V., &#x201c;Antiretroviral Therapy&#x2010;Induced Insulin Resistance and Oxidative Deoxy Nucleic Acid Damage in Human Immunodeficiency Virus&#x2010;1 Patients,&#x201d; Indian Journal of Endocrinology and Metabolism 21, no. 2 (2017): 316, 10.4103/2230-8210.202029.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2230-8210.202029</ArticleId><ArticleId IdType="pmc">PMC5367237</ArticleId><ArticleId IdType="pubmed">28459032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S. P., Wu C.&#x2010;Y., Wang C.&#x2010;B., Li T.&#x2010;C., Ko N.&#x2010;Y., and Shi Z.&#x2010;Y., &#x201c;Risk of Diabetes Mellitus in HIV&#x2010;Infected Patients Receiving Highly Active Antiretroviral Therapy: A Nationwide Population&#x2010;Based Study,&#x201d; Medicine 97, no. 36 (2018): e12268, 10.1097/MD.0000000000012268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000012268</ArticleId><ArticleId IdType="pmc">PMC6133418</ArticleId><ArticleId IdType="pubmed">30200166</ArticleId></ArticleIdList></Reference><Reference><Citation>Antony I., Kannichamy V., Banerjee A., Gandhi A. B., Valaiyaduppu Subas S., and Hamid P., &#x201c;An Outlook on the Impact of HIV Infection and Highly Active Antiretroviral Therapy on the Cardiovascular System&#x2013;A Review,&#x201d; Cureus 12, no. 11 (2020): 11539, 10.7759/cureus.11539.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.11539</ArticleId><ArticleId IdType="pmc">PMC7746328</ArticleId><ArticleId IdType="pubmed">33354483</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho N. H., Shaw J. E., Karuranga S., et al., &#x201c;IDF Diabetes Atlas: Global Estimates of Diabetes Prevalence for 2017 and Projections for 2045,&#x201d; Diabetes Research and Clinical Practice 138 (2018): 271&#x2013;281, 10.1016/j.diabres.2018.02.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabres.2018.02.023</ArticleId><ArticleId IdType="pubmed">29496507</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehman S., Rehman E., Ikram M., and Jianglin Z., &#x201c;Cardiovascular Disease (CVD): Assessment, Prediction and Policy Implications,&#x201d; BMC Public Health 21, no. 1 (2021): 1299, 10.1186/s12889-021-11334-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-021-11334-2</ArticleId><ArticleId IdType="pmc">PMC8253470</ArticleId><ArticleId IdType="pubmed">34215234</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D., Shamseer L., Clarke M., et al., &#x201c;Preferred Reporting Items for Systematic Review and Meta&#x2010;Analysis Protocols (PRISMA&#x2010;P) 2015 Statement,&#x201d; Systematic Reviews 4, no. 1 (2015): 1, 10.1186/2046-4053-4-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2046-4053-4-1</ArticleId><ArticleId IdType="pmc">PMC4320440</ArticleId><ArticleId IdType="pubmed">25554246</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden J. A., van der Windt D. A., Cartwright J. L., C&#xf4;t&#xe9; P., and Bombardier C., &#x201c;Assessing Bias in Studies of Prognostic Factors,&#x201d; Annals of Internal Medicine 158, no. 4 (2013): 280&#x2013;286, 10.7326/0003-4819-158-4-201302190-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-158-4-201302190-00009</ArticleId><ArticleId IdType="pubmed">23420236</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne J. A., Hern&#xe1;n M. A., Reeves B. C., et al., &#x201c;Robins&#x2010;I: A Tool for Assessing Risk of Bias in Non&#x2010;Randomised Studies of Interventions,&#x201d; BMJ 355 (2016): i4919, 10.1136/bmj.i4919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i4919</ArticleId><ArticleId IdType="pmc">PMC5062054</ArticleId><ArticleId IdType="pubmed">27733354</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg T., Heymans M. W., Leone S. S., et al., &#x201c;Overview of Data&#x2010;Synthesis in Systematic Reviews of Studies on Outcome Prediction Models,&#x201d; BMC Medical Research Methodology 13, no. 1 (2013): 42, 10.1186/1471-2288-13-42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-13-42</ArticleId><ArticleId IdType="pmc">PMC3626935</ArticleId><ArticleId IdType="pubmed">23497181</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabane L., Mbuagbaw L., Zhang S., et al., &#x201c;A Tutorial on Sensitivity Analyses in Clinical Trials: The What, Why, When and How,&#x201d; BMC Medical Research Methodology 13, no. 1 (2013): 92, 10.1186/1471-2288-13-92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-13-92</ArticleId><ArticleId IdType="pmc">PMC3720188</ArticleId><ArticleId IdType="pubmed">23855337</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x201c;Definition of Levels of Evidence (LoE) and Overall Strength of Evidence (SoE),&#x201d; Global Spine Journal 5, no. 6 (2015): 539, 10.1055/s-0035-1570346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0035-1570346</ArticleId><ArticleId IdType="pmc">PMC4671889</ArticleId><ArticleId IdType="pubmed">26682110</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>